A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer

Ji-Guang Han; Yong-Dong Jiang; Chun-Hui Zhang; Yan-Mei Yang; Da Pang; Yan-Ni Song; Guo-Qiang Zhang

추천

검색

질문

자료유형: 학술저널

저자정보: Ji-Guang Han (The Third Affiliated Hospital of Harbin Medical University) Yong-Dong Jiang (The Third Affiliated Hospital of Harbin Medical University) Chun-Hui Zhang (The Third Affiliated Hospital of Harbin Medical University) Yan-Mei Yang (Harbin Medical University) Da Pang (The Third Affiliated Hospital of Harbin Medical University) Yan-Ni Song (The Third Affiliated Hospital of Harbin Medical University) Guo-Qiang Zhang (The Third Affiliated Hospital of Harbin Medical University)

저널정보: 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.92 No.2

발행연도: 2017.2

수록면: 55 - 66 (12page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Insufficient sensitivity and specificity prevent the use of most existing biomarkers for early detection of breast cancer. Recently, it was reported that serum microRNAs (miRNAs) may be potential biomarkers in many cancer diseases. In this study, we investigated whether serum levels of 5 miRNAs including miR-21, miR-125b, miR-145, miR-155, and miR-365 could discriminate breast cancer patients and healthy controls.
Methods: Serum levels of miRNAs were measured by using quantitative real-time polymerase chain reaction in 99 breast cancer patients and 21 healthy controls. The abundance change of serum miRNAs were also evaluated following surgical resection in 20 breast cancer patients. Receiver operating characteristic (ROC) curve analysis was performed to assess the sensitivity and specificity of miRNAs as diagnostic biomarkers.
Results: Serum levels of miR-21 and miR-155 was significantly higher, while miR-365 was significantly lower in breast cancer as compared with healthy controls. The serum levels of miR-21 and miR-155 significantly decreased following surgical resection. Additionally, the serum level of miR-155 at stages I and II was significantly higher compared to stage III. The serum miR-145 level was remarkably higher in progesterone receptor (PR)-positive patients than PR-negative. The positivity of miR-21, miR-155, and miR-365 was high compared to CA 153 and CEA in breast cancer. ROC curve analyses of a combination of miR-21, miR-155, and miR-365 yielded much higher area under curve and enhanced sensitivity and specificity in comparison to each miRNA alone.
Conclusion: The combination of serum miR-21/miR-155/miR-365 may potentially serve as a sensitive and specific biomarker that enables differentiation of breast cancer from healthy controls.

#Serum #MicroRNAs #miRNA-21 #miRNA-155 #miRNA-365 #Breast neoplasms

참고문헌 (30)

참고문헌 신청

[학술지(정기간행물)] - Schettini F / 2016 / Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer : Where we are now and where we are going / Cancer Treat Rev 46 : 20 ~ 26

[학술지(정기간행물)] - Duffy MJ. / 2007 / Role of tumor markers in patients with solid cancers : a critical review / Eur J Intern Med 18 : 175 ~ 184

[학술지(정기간행물)] - Pileczki V / 2016 / MicroRNAs as regulators of apoptosis mechanisms in cancer / Clujul Med 89 : 50 ~ 55

[학술지(정기간행물)] - Solomides CC / 2012 / MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis / Acta Cytol 56 : 645 ~ 654

[학술지(정기간행물)] - Markou A / 2013 / Clinical evaluation of microRNA expression profiling in non small cell lung cancer / Lung Cancer 81 : 388 ~ 396

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!